Introduction {#Sec1}
============

The Sepsis-3 consensus defines sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to infection \[[@CR1]\]. While our understanding of sepsis pathophysiology is increasing, controversies in haemodynamic management persist \[[@CR2], [@CR3]\]. The most recent surviving sepsis guidelines recommend noradrenaline as the first-choice vasopressor because of its vasopressor and positive inotropic properties \[strong recommendation, moderate quality of evidence \[[@CR4]\]\]. In contrast, the concept of 'decatecholamisation' emerged in the last decade stemming from the recognized negative effects of catecholamines in sepsis \[[@CR3], [@CR5], [@CR6]\]. Interestingly, the β-adrenergic blockade has emerged as a possible treatment option for blunting the adrenergic response in early sepsis with potential effects on the modulation of cardiogenic, metabolic, immunologic, and coagulopathic derangements in sepsis \[[@CR7]\].

Early administration of the short-acting β-blocker esmolol in a recent trial showed a reduction in 28-day sepsis mortality \[[@CR8], [@CR9]\]. Furthermore, some studies have suggested a benefit of premorbid β-blocker exposure on sepsis outcomes \[[@CR10], [@CR11]\]. Multiple systematic reviews have since concluded that there is limited preliminary evidence for the use of β-blockers during sepsis \[[@CR12]--[@CR14]\], while others are skeptical \[[@CR15]\]. However, to date, no published systematic review exists on the effects of premorbid β-blocker exposure on sepsis outcomes, including mortality. Therefore, we set out to systematically examine the evidence from all human studies on premorbid β-blocker exposure and sepsis.

Materials and methods {#Sec2}
=====================

This study follows the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines \[[@CR16]\] and was registered with the international prospective register of systematic reviews (PROSPERO; CRD 42019130558). The MOOSE checklist is appended as Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Data sources and searches {#Sec3}
-------------------------

Three databases, EMBase, MEDLINE, and Cochrane were searched on 30 January 2019 for records dating from database conception to the date of search that was last updated on 22 June 2019. The search was only limited to human research. Duplicates were removed using the Ovid platform and checked for any incorrect removal. Hand searching from reference lists was also performed. The full search strategy is appended as Additional file [4](#MOESM4){ref-type="media"}: Figure S1.

Study selection {#Sec4}
---------------

Inclusion criteria for this review were guided by the 'Patient, Population, or Problem, Intervention, Comparison, Outcome, Study Design or Setting' (PICOS) framework \[[@CR17]\] (Table [1](#Tab1){ref-type="table"}). Patients exposed to β-blockers prior to an episode of sepsis or septic shock and were cared for in the emergency department (ED) or intensive care unit (ICU) were included in this review. Observational studies were eligible. Excluded were case studies/small series (\< 20 patients overall) and review articles. The abstracts were assessed by two investigators (KT, MH) independently, and disagreements were resolved with a third investigator (MN). Table 1'PICOS' approach for selecting clinical studies in the systematic search. PICOS Patient, Population, or Problem, Intervention, Comparison, Outcome, Study Design or SettingPICOSStudy characteristics1. ParticipantsPatients with sepsis and/or septic shock2. InterventionPremorbid exposure to beta blockers3. ComparisonNo premorbid exposure to beta blockers4. OutcomesMortality5. Study designProspective observational or retrospective cohort studies

Data extraction and quality assessment {#Sec5}
--------------------------------------

Data from eligible studies were independently extracted by two investigators (KT, MH). Where required, study authors were contacted directly to kindly provide missing research data. The Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool \[[@CR18]\] was used to independently assess (KQ, MH) the quality of studies.

Data synthesis and analysis {#Sec6}
---------------------------

Adjusted outcome data were combined using the inverse variance method \[[@CR19]\]. Heterogeneity between studies was measured by Higgin's and Thomson's *I*^2^ \[[@CR20]\]. Statistical analyses were performed using Review Manager version 5.3 (Copenhagen: The Cochrane Collaboration, 2014)

Results {#Sec7}
=======

Study selection {#Sec8}
---------------

The initial search returned 2128 abstracts, all in English. Two thousand sixty-four abstracts were manually screened after removal of 64 duplicates. After screening, 16 studies were initially selected for data extraction. Where required, the corresponding authors were contacted to obtain necessary data for statistical analysis. Seven studies were excluded for not meeting all inclusion criteria. The list of studies excluded is appended (Additional file [2](#MOESM2){ref-type="media"}: Table S2). Overall, a total of nine studies were found to be eligible, comprising 56,414 patients with sepsis, including 6576 patients with premorbid exposure to β-blockers (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Flow diagram of the study selection process

Characteristics and type of studies {#Sec9}
-----------------------------------

All studies were retrospective cohort studies, and the data were collected between 1999 and 2017.

The study populations described patients with sepsis, severe sepsis, or septic shock in an ED \[[@CR21]\] or ICU \[[@CR10], [@CR11], [@CR21]--[@CR26]\] setting. The definitions of sepsis, severe sepsis, septic shock, and premorbid β-blocker exposure varied slightly across the studies, but were reasonable and comparable to current definitions \[[@CR1]\]. Two studies \[[@CR10], [@CR27]\] included patients with sepsis, severe sepsis, and septic shock, while seven studies \[[@CR11], [@CR21]--[@CR26]\] included patients with severe sepsis and/or septic shock. One study (Alsolamy et al.) included patients ≥ 14 years of age; all other studies included adult (18 years and above) patients. Four studies by Sharma et al., Charles et al., Alsolamy et al., and Al-Qadi et al. were reported as conference abstracts \[[@CR22]--[@CR25]\]. The characteristics of the studies are appended (Table [2](#Tab2){ref-type="table"}). Table 2Characteristics of included studiesFirst authorYear of publicationType of studyStudy period (month/year)CountryNumber of centresDiagnosisSetting (ED/ICU)ICU type (medical/surgical)OutcomePremorbid beta blocker exposureInclusionsExclusionsSelect cohortNo. of patients with premorbid beta blocker useSinger et al. \[[@CR11]\]2017Retrospective matched cohort study2009--2011USAMedicare Provider and Analysis Review dataSevere sepsis, septic shockICUMixedPrimary: mortalityFilled prescription within 30 days of admission, including date of admission. Data obtained from Medicare Part D claims data.Patients admitted with an urgent/emergent hospital admission code, requiring intensive care upon admission, and carrying a primary diagnosis of sepsis or systemic inflammatory response syndrome (SIRS) by ICD9 diagnosis codes, \> 65 years, asthma, heart block, 1 year of continuous Part A and Part B coverage, with Part D enrolment.In hospital claims without ICU admission, Part C enrolment (coverage through healthcare maintenance organizations), beta blocker prescriptions extending into 30 days prior to admission but not through the admission date.68392838Macchia et al. \[[@CR10]\]2012Retrospective matched cohort study2003--2008Italy22SepsisICUMixedPrimary: mortality3 or more filled prescriptions within 4 months of admission. Data obtained from local health authority drug claims database.Sepsis with codes 038 \[septicemia\], 020.0 \[septicemic\], 790.7 \[bacteremia\], 117.9 \[disseminated fungal infection\], 112.5 \[disseminated candida infection\], and 112.81 \[disseminated fungal endocarditis\]. Admission direct to ICU or transferred to ICU from other hospital departments within 48 h of admission.\< 40 years old, transfer to ICU from other departments 48 h after admission.94651061Hsieh et al. \[[@CR27]\]2019Retrospective matched observational study1999--2013TaiwanNational Health Insurance Research Database (NHIRD) of Taiwan dataSepsis, septic shock----Primary: mortalityPatients were classified as using certain drugs if they took them for more than 1 week within a 3-month period prior to the index date.First episode of severe sepsis or septic shock. ICD-9-CM coding was used.Second episode of sepsis.33,2131040Fuchs et al. \[[@CR26]\]2017Secondary analysis of prospective observational single-centre trial2010--2013Germany1Sepsis, severe sepsis, septic shockICUSurgicalPrimary: mortality; survival analysisSecondary: length of stayPre-existing oral beta blocker therapy was defined as a treatment started at least 7 days before sepsis onset.First episode of severe sepsis or septic shock.\< 18 years old, no infection, no chronic beta blocker therapy, no sepsis or septic shock, second episode of sepsis.296296Contenti et al. \[[@CR21]\]2015Retrospective cohort study2012--2014France1Severe sepsis, septic shockED/ICU--Primary: initial blood lactate concentration.Secondary: mortality'Premorbid' not defined. Data obtained from ED observation data or inpatient records\> 18 years old, severe sepsis, septic shock.--26065Sharma et al. \[[@CR25]\]2016Retrospective study2013--2014ICUNot specifiedSeptic shockICUMedicalPeak lactate, cumulative norepinephrine dose and duration, mortality'Premorbid' not defined. Data obtained from ICU medical records.Medical ICU, septic shock, vasopressors required.--12348Charles et al. \[[@CR23]\]2018Retrospective study2008--2016FranceNot specifiedSeptic shockICU--Heart rate, arterial lactate levels, arterial oxygen content, fluid requirements, norepinephrine requirements, duration of mechanical ventilation, mortality'Premorbid' not defined.Adult patients diagnosed with septic shock within 48 h.--938230Alsolamy et al. \[[@CR22]\]2016Retrospective cohort study1/1/2003--31/12/2013Saudi Arabia1Severe sepsis, septic shockICU--Primary: mortalityActive prescription 3 months prior to admission.\> 14 years old, severe sepsis and septic shock, previous prescription of beta blockers active for 3 months prior to hospital admission.--4629623Al-Qadi et al. \[[@CR24]\]2014Retrospective study2007--2009USA1Severe sepsis, septic shockICUMedicalPrimary: mortality3 or more months of beta blocker usage prior to admission. Data obtained from electronic records.Severe sepsis and septic shock, 3 or more months on beta blocker prior to ICU admission.Patients with comfort care.651375

Risk of bias assessment {#Sec10}
-----------------------

All observational studies of premorbid medication use are at risk of bias because of confounding. Five studies included in this review \[[@CR10], [@CR11], [@CR24], [@CR26], [@CR27]\] were judged to be of moderate risk of bias for the primary outcome of mortality as they reported adjustment of confounding variables via statistical analysis. Four studies \[[@CR21]--[@CR23], [@CR25]\] were judged as having serious risk of bias due to confounding as the authors did not perform statistical analysis to correct for confounders. The risk of bias assessment using ROBINS-1 tool for each trial is appended (Additional file [5](#MOESM5){ref-type="media"}: Figure S2) with reasonings attached (Additional file [3](#MOESM3){ref-type="media"}: Table S3).

Primary outcome: mortality {#Sec11}
--------------------------

The smallest study by Contenti et al. included 260 sepsis patients. Results from that study showed a non-significant decrease in 28-day mortality (35% vs 49%, *p* = 0.08; Table [3](#Tab3){ref-type="table"}). Using multivariate logistic regression, three studies by Singer et al., Macchia et al., and Hsieh et al. reported mortality data as adjusted odds ratios \[[@CR10], [@CR11], [@CR27]\]. Singer et al. reported a decrease in hospital mortality in patients with severe sepsis and septic shock (aOR = 0.69; 95% CI \[0.62, 0.77\]; Table [3](#Tab3){ref-type="table"}). Subgroup analysis between cardioselective β-blockers and non-selective β-blockers showed that non-selective β-blockers were associated with lower hospital mortality, adjusted OR for non-selective β-blockers (aOR = 0.59; 95% CI \[0.49, 0.71\]) compared to cardioselective β-blockers (aOR = 0.73; 95% CI \[0.65, 0.82\]). Overall mortality rate for cardioselective β-blocker users was higher, cardioselective β-blocker users vs. non-selective β-blocker users (aOR = 1.23; 95% CI \[1.11--1.36\]). Hospital mortality was also reduced across all age groups: between ages 65 and 74 (aOR = 0.64; 95% CI \[0.52, 0.80\]), between ages 75 and 84 (aOR = 0.69; 95% CI \[0.58, 0.83\]), and above 85 (aOR = 0.73; 95% CI \[0.60, 0.90\]). Table 3Mortality data for included studies. Premorbid beta blocker exposure vs no premorbid beta blocker exposureFirst authorSelect cohortNo. of patients with no premorbid beta blocker useNo. of patients with premorbid beta blocker useMortality census dayMortality90-day mortality28-day mortalityICU mortalityHospital mortalitySurvival analysisOutcomeAdjustment methodAdjusted variablesSinger et al. \[[@CR11]\]683940012838Hospital mortality--------aOR = 0.69 (CI 0.62--0.77)--Premorbid beta blocker usage is significantly associated with decreased mortalityMultivariate logistic regressionAge, class of beta blocker, congestive heart failure, cancer, surgical proceduresMacchia et al. \[[@CR10]\]94658404106128-day mortality----aOR = 0.81 (CI 0.68--0.97), *p* = 0.025------Premorbid beta blocker usage is significantly associated with decreased mortalityMultivariate logistic regressionAge, sex, history of hypertension, dyslipidaemia, diabetes mellitus, myocardial infarction, congestive heart failure, atrial fibrillation, chronic obstructive pulmonary disease, depression, and malignancyHsieh et al. \[[@CR27]\]33,21332,1731040Hospital mortality--------aOR = 0.89 (CI 0.76--1.04), *p* = 0.1484--Premorbid beta blocker usage is not significantly associated with decreased mortalityMultivariate logistic regressionAge, sex, insurance premium, urbanization level, and comorbiditiesFuchs et al.^a^ \[[@CR26]\]2960296ICU, hospital, 28 days, 90 days--40.7% vs. 52.7%, *p* = 0.046^a^28.7% vs. 41.1%, *p* = 0.04^a^27.5% vs. 38%, *p* = 0.06^a^35.3% vs. 48.1%, *p* = 0.03^a^HR = 0.67 (CI 0.48, 0.95), *p* = 0.03^a^Continuation of beta-blockade is associated with decreased 28-day, 90-day, and hospital mortality.Multivariate cox regressionSex, known nosocomial pathogen, chronic diseases, body temperature (\< 36.0 °C), APACHE II score first 24 h, lactate first 24 h (\> 3 mmol/L)Contenti et al. \[[@CR21]\]2601956528-day mortality--------35% vs 49%, *p* = 0.08--Premorbid beta blocker usage is not significantly associated with decreased mortality----Sharma et al. \[[@CR25]\]1237548Hospital mortality--------35.4% vs 32%, *p* = 0.70--Premorbid beta blocker usage is not significantly associated with decreased mortality----Charles et al. \[[@CR23]\]938708230ICU mortality------35.7% vs. 37%, *p* = 0.75----Premorbid beta blocker usage is not significantly associated with decreased mortality----Alsolamy et al. \[[@CR22]\]46294006623ICU mortality------RR = 0.94 (CI 0.82--1.08), *p* = 0.39----Premorbid beta blocker usage is not significantly associated with decreased mortality----Al-Qadi et al. \[[@CR24]\]651276375Not specified21.3% vs 27.2%, *p* = 0.09; aOR 0.62, *p* = 0.023----------Premorbid beta blocker usage is not significantly associated with decreased mortality--Age, gender, and severity of illness using SOFA and APACHE III scores^a^Continued beta blocker usage during sepsis vs discontinued beta blocker usage during sepsis

Macchia et al. reported a significant decrease in 28-day mortality in patients with sepsis (aOR = 0.81; 95% CI \[0.68--0.97\]; *p* = 0.025; Table [3](#Tab3){ref-type="table"}). Subgroup analysis investigating the effect of age, gender, organ dysfunction, and previous comorbidities did not alter the results. Adjustment for previous medication used including calcium channel blockers, amiodarone, angiotensin-converting-enzyme inhibitors, diuretics, or any nonsteroidal anti-inflammatory drugs also did not alter the results. The authors also conducted a propensity matching analysis, which led to similar results (OR = 0.72; 95% CI \[0.57--0.91\]; *p* = 0.04).

The study by Hsieh et al. showed that premorbid β-blocker exposure was not associated with a significant decrease in hospital mortality in patients with sepsis and septic shock (aOR = 0.89; 95% CI \[0.76, 1.04\]; *p* = 0.1484; Table [3](#Tab3){ref-type="table"}). However, subgroup analysis of patients with septic shock showed that premorbid β-blocker exposure was significantly associated with decreased hospital mortality (aOR = 0.68; 05% CI \[0.56, 0.82\]; *p* = 0.0001). In patients without septic shock, premorbid β-blocker exposure was associated with significantly higher mortality (aOR = 1.16; 95% CI \[1.11, 1.21\]; *p* \< 0.0001).

We compared the mortality data from the three studies that adjusted for potential confounders. Pooled analysis of the three studies showed an average odds ratio, aOR = 0.79; 95% CI (0.67, 0.92), *p* = 0.004; Fig. [2](#Fig2){ref-type="fig"}. However, there was substantial heterogeneity (*i*^2^ = 74%) between the studies, indicating that a meta-analysis is premature and that further studies and subgroup analyses are needed to validate the results. Fig. 2Adjusted odds ratio analysis via forest plot of sepsis mortality rates in studies comparing populations with premorbid β-blocker (BB) exposure to populations without premorbid β-blocker exposure. Horizontal bars represent 95% confidence intervals

Our systematic search also included grey literature in the form of conference abstracts. Mortality data from three studies reported as conference abstracts showed a trend towards a decrease in mortality with premorbid β-blocker exposure. However, the results were not statistically significant: Charles et al. (ICU mortality; 35.7% vs. 37%, *p* = 0.75), Alsolamy et al. (ICU mortality; RR = 0.94 (CI: 0.82--1.08), *p* = 0.39), and Al-Qadi et al. (21.3% vs 27.2%, *p* = 0.09) (Table [3](#Tab3){ref-type="table"}). Of note, the study by Alsolamy et al. included patients ≥ 14 years old, while all other studies only included adults. Another retrospective study, reported as a conference abstract, involving 123 sepsis patients showed a non-significant increase in mortality with premorbid β-blocker exposure: Sharma et al. (hospital mortality; 35.4% vs 32%, *p* = 0.70; Table [3](#Tab3){ref-type="table"}).

One interesting study by Fuchs et al. investigated the effect of continuing premorbid β-blocker use in patients with severe sepsis and septic shock. This study included 296 patients on chronic β-blockers, in which β-blockade was continued in 176 patients. Results showed that continuation of β-blockade during sepsis was associated with decreased 28-day (28.7% vs. 41.1%, *p* = 0.04), 90-day (40.7% vs. 52.7%, *p* = 0.046), and hospital mortality (35.3% vs. 48.1%, *p* = 0.03) (Table [3](#Tab3){ref-type="table"}). Survival analysis also indicated that continuation of β-blockade during sepsis is significantly associated with decreased mortality (HR = 0.67; 95% CI \[0.48, 0.95\]; *p* = 0.03; Table [3](#Tab3){ref-type="table"}).

Clinical parameters {#Sec12}
-------------------

Only four studies by Contenti et al. \[[@CR21]\], Charles et al. \[[@CR23]\], Sharma et al. \[[@CR25]\], and Fuchs et al. \[[@CR26]\] provided clinical parameter data. However, reporting of parameters was inconsistent. There was no significant difference in the requirements for vasopressor infusion across all four studies. Contenti et al. and Charles et al. found that premorbid β-blocker exposure was associated with decreased heart rate; Sharma et al., did not report heart rate data. Continuation of β-blockade during sepsis was not associated with a decrease in heart rate in the first 24 h \[[@CR26]\]. Premorbid β-blocker use was found to be associated with lower initial plasma lactate levels by Contenti et al., but not by Charles et al.. The continuation of β-blockade during sepsis was associated with lower plasma lactate levels in the first 24 h \[[@CR26]\].

There were no significant differences in all other relevant parameters including mean arterial pressure, Sequential Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation (APACHE)-II or III score, and incidence of mechanical ventilation. The clinical parameter data are presented in Table [4](#Tab4){ref-type="table"}. Table 4Reported clinical parametersFirst authorHeart rateInitial blood lactate levelsPeak blood lactate levelsCreatinine levelsArterial pHMean arterial pressureSOFA scoreAPACHE II scoreAPACHE III scoreMechanical ventilationVasopressor infusionContenti et al.^a^ \[[@CR21]\]100 ± 25 vs 109 ± 25 bpm; *p* = 0.023.9 ± 2.3 mmol/L vs 5.6 ± 3.6 mmol/L; *p* = 0.0006------72 mmHg ± 22 vs 70 mmHg ± 21; *p* = 0.485.0 ± 2.8 vs 5.3 ± 2.8; *p* = 0.4421.0 ± 6.0 vs 21.7 ± 6.9; *p* = 0.41--15% vs 19%; *p* = 0.5831% vs 32%; *p* = 0.94Sharma et al.^a^ \[[@CR25]\]----3.2 vs 3.6 mmol/L; *p* = 0.54----------94 vs 84; *p* = 0.14--Cumulative dose 11.4 vs 12.6 mg; *p* = 0.43Duration of infusion 1563 vs 1730 min; *p* = 0.37Charles et al.^a^ \[[@CR23]\]81 (IQR 82--111) vs. 107 (IQR 89--122) bpm; *p* \< 0.011.75 (IQR 0.9--3.4) vs. 1.8(IQR 0.8--4) mmol/L; *p* = 0.97--165.5 (IQR 108--245) vs 135.5 (IQR 82--108); *p* \< 0.007.35 (IQR 7.25--7.42) vs 7.34 (IQR 7.23--7.42); *p* = 0.354--9 (IQR 6--12) vs 9 (IQR 6--13); *p* = 0.242----81.7% vs 84.9%; *p* = 0.112Days on ventilation 4 (IQR 2--9) vs 5.5 (IQR 2--11); *p* = 0.05523.2 mg (IQR 5.1--57.0) vs 22.4 mg (IQR 5.2--60.5); *p* = 0.95Fuchs et al.^b^ \[[@CR26]\]111 (IQR 97.0--132.8) vs 118 (IQR 97.0--135.5); *p* = 0.22.3 (IQR 1.5--3.8) vs 3.5 (IQR 2.0--6.5); *p* \< 0.01----------20.0 (IQR 15.0--24.5) vs 21.0 (IQR 16.2--26.0); *p* = 0.25----Norepinephrine 91% vs 92.2%; *p* = 0.83^a^Premorbid beta blocker exposure vs no premorbid beta blocker exposure^b^Continued beta blocker usage during sepsis vs discontinued beta blocker usage during sepsis

Discussion {#Sec13}
==========

This is the first systematic review examining the role of premorbid β-blocker exposure on mortality outcomes in patients with sepsis. While there was not enough data to conduct a meta-analysis, pooled adjusted odds ratio from three studies indicated a potential decrease in mortality associated with premorbid β-blocker use, albeit with substantial heterogeneity. Our results provide preliminary evidence of a potential association between premorbid β-blocker use and mortality in sepsis and add to the emerging evidence suggesting harmful effects of adrenergic stress on mortality in sepsis. We discuss the effects of premorbid β-blocker exposure on the adrenergic response in early sepsis.

Cardiac dysfunction in sepsis is common and has both systolic and diastolic components \[[@CR5]\]. However, only diastolic dysfunction seems to be associated with mortality \[[@CR28], [@CR29]\]. While being on premorbid β-blockers may reduce systolic function, the reduction of adrenergic response in sepsis (decreasing heart rate, prolongation of diastolic time, and improved coronary perfusion) can lead to mitigation of diastolic dysfunction \[[@CR28], [@CR29]\]. Further, the risks of myocardial ischemia may be decreased due to reduced myocardial oxygen consumption \[[@CR14]\].

Patients with septic shock are often treated with large doses of exogenous catecholamines for haemodynamic stabilization. The most recent Surviving Sepsis Campaign guidelines recommend using noradrenaline as the first-line agent for vasopressor therapy, with adrenaline or low-dose vasopressin as second-line agents \[[@CR4]\]. Increased dosage and duration of noradrenaline administration has been associated with higher incidence of new onset atrial fibrillation \[[@CR3]\]. Excessive catecholamine levels may also play an important role in sepsis-related cardiac dysfunction by causing cardiomyopathy and cardiomyocyte necrosis \[[@CR5], [@CR7]\]. β-adrenergic blockade could reduce the amount of exogenous catecholamines used by restoring sepsis-induced downregulation of β-adrenergic receptors \[[@CR12], [@CR30]\]. Four of the included studies in this systematic review, however, found that premorbid β-blocker exposure was not associated with a significant difference in vasopressor requirements during sepsis. Similarly, Fuchs et al. found that continuing chronic beta blockers during acute phase of sepsis is not associated with increased use of catecholamines.

Interestingly, Singer et al. reported that patients with premorbid exposure to non-selective β-blockers had lower mortality rates compared to patients with premorbid cardioselective β-blocker exposure \[[@CR11]\]. This suggests that β-blocker modulation of non-cardiac adrenergic responses to sepsis may also have an important role. Furthermore, β-blockers may potentially positively modulate the disturbed autonomic (sympathetic-parasympathetic) balance in sepsis \[[@CR31]\].

Adrenergic response to sepsis induces a hypermetabolic state characterized by increased energy expenditure, hyperglycaemia, lipolysis and proteolysis, supressed ketogenesis, and negative nitrogen balance resulting in eventual loss of lean body mass \[[@CR32]\]. β2-adrenergic blockade appears to have the potential to reverse hyperglycaemia and reduce proteolysis \[[@CR7]\]. For example, the use of propranolol in children with severe burns appears to attenuate hypermetabolism and reverse muscle catabolism \[[@CR33]\].

The immune system is also modulated by the adrenergic responses to sepsis \[[@CR34]\]. The β-adrenergic system regulates apoptosis, mitochondrial function, and inflammatory cytokine production. β-blockers influence the pattern of cytokine synthesis with β1 blockers downregulating a proinflammatory response, whereas β2-antagonization seems to have an opposite effect, at least in chronic heart failure \[[@CR35]\].

In sepsis, β2-adrenergic stimulation selectively inhibits CD4^+^ lymphocyte Th1 function and favours the Th2 responses that inhibit macrophage activation, T cell proliferation, and proinflammatory cytokine production \[[@CR7]\]. CD8^+^ lymphocyte function may also be suppressed by β2-adrenergic stimulation \[[@CR36]\]. The derangement in lymphocytic function induced by catecholamines is thus reminiscent of sepsis-induced immune suppression and could even be considered as one of the mechanisms. However, to date, the evidence for any beneficial use of β-adrenergic blockade on immune function in sepsis has been conflicting \[[@CR7]\].

Sepsis results in a pro-thrombotic state with increases in plasma tissue factor and von Willebrand factor levels \[[@CR37]\]. Platelets also express adrenergic receptors on their surface \[[@CR38]\]. However, there are conflicting effects of β1 and β2 pathways on platelet function \[[@CR7]\]. The use of β-adrenergic blockade led to decreased endothelial cell damage in a murine model of shock coagulopathy \[[@CR39]\]. This suggests that premorbid β-blocker therapy might mitigate shock-induced endotheliopathy (SHINE), attenuating sepsis-associated coagulopathy \[[@CR40]\].

Nonetheless, multiple questions on the role of β-adrenergic blockade in sepsis remain unanswered. On top of safety and efficacy concerns, the duration and dosage at which β-blockade should be performed remain to be elucidated. Furthermore, the timing of therapeutic β-adrenergic blockade initiation is also controversial. The results of our systematic review suggest that we should not discount β-blockers during sepsis. Instead, we may consider continuing chronic β-blockers and perhaps introduce β-blocking drugs early in the sepsis management, especially the non-cardioselective ones.

Strengths and limitations {#Sec14}
-------------------------

This study analysed data from nine observational studies, four of which were reported as conference abstracts. There was not enough data to conduct a meta-analysis. By nature of observational studies, systematic confounding and risk of bias cannot be ruled out. The risk of bias can be reduced by adjusted analysis. Analysis of pooled adjusted odds ratio revealed a significant decrease in sepsis mortality with premorbid β-blocker exposure, but adjusted data were available only from three studies. Despite the three studies providing data on the majority of patients included in this review, substantial heterogeneity is present and residual confounding is likely. Potential sources of confounding include the variable definitions of premorbid β-blocker exposure used by the included studies, the appropriate prescription of β-blockers to all included patients, and patient compliance to treatment.

The conclusions that can be drawn from this study are also hampered by the lack of clinical parameter data, limiting our ability to decipher the likely mechanism/s by which premorbid β-blocker exposure may lower sepsis mortality.

Conclusion {#Sec15}
==========

This systematic review suggests that β-blocker exposure prior to an episode of sepsis could have a role in reducing sepsis mortality. More evidence, however, is needed to elucidate whether premorbid β-blocker treatment is able to mitigate, and by what mechanism, the potentially detrimental effects of endogenous or exogenous catecholamines in early sepsis. Further appropriately powered and ideally prospective observational studies on premorbid β-blocker exposure will be necessary to generate the required evidence.
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